Insulin signalling sensitizers (e.g. pioglitazone and metformin) that commonly used in treating diabetes have proven clinically beneficial in improving biochemical indices in NAFLD patients [11]. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.